AdaptHealth Corp. (NASDAQ:AHCO) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of AdaptHealth Corp. (NASDAQ:AHCO) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $11.67.

Several research analysts recently issued reports on the company. Truist Financial cut their price objective on AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Canaccord Genuity Group cut their price target on AdaptHealth from $14.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Royal Bank of Canada decreased their price objective on AdaptHealth from $13.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 19th. UBS Group cut their target price on shares of AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Robert W. Baird cut their price objective on shares of AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board purchased a new position in AdaptHealth in the second quarter valued at approximately $58,000. Quarry LP increased its position in shares of AdaptHealth by 4,596.9% in the third quarter. Quarry LP now owns 5,965 shares of the company’s stock worth $67,000 after acquiring an additional 5,838 shares in the last quarter. Innealta Capital LLC purchased a new position in shares of AdaptHealth in the 2nd quarter valued at $101,000. Quest Partners LLC lifted its holdings in shares of AdaptHealth by 11,522.7% during the 2nd quarter. Quest Partners LLC now owns 10,228 shares of the company’s stock valued at $102,000 after acquiring an additional 10,140 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in AdaptHealth during the 2nd quarter worth $113,000. Institutional investors and hedge funds own 82.67% of the company’s stock.

AdaptHealth Stock Down 1.2 %

AdaptHealth stock opened at $10.05 on Thursday. AdaptHealth has a fifty-two week low of $6.46 and a fifty-two week high of $11.90. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -6.09, a price-to-earnings-growth ratio of 1.36 and a beta of 1.10. The stock’s fifty day moving average is $10.09 and its two-hundred day moving average is $10.44. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.00 and a current ratio of 1.24.

AdaptHealth (NASDAQ:AHCO) last posted its earnings results on Tuesday, November 5th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.02). The business had revenue of $805.90 million for the quarter, compared to analysts’ expectations of $809.32 million. AdaptHealth had a negative net margin of 6.57% and a positive return on equity of 9.62%. The business’s revenue was up .2% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 earnings per share. Analysts predict that AdaptHealth will post 0.88 EPS for the current fiscal year.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.